Continued access to remibrutinib after a prior study
Treatments studied
This trial lets people who have been benefiting from remibrutinib in an earlier Novartis study continue receiving the drug after their original study ends. It's an open-label roll-over study, meaning everyone knows they're getting remibrutinib and it's designed to provide ongoing treatment for those who need it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have completed treatment in a prior Novartis study of remibrutinib for a skin or allergy condition.
- You are still getting benefit from remibrutinib and your doctor thinks you will continue to benefit.
- The benefit of taking remibrutinib outweighs any risks, in your doctor's judgment.
- You cannot get the marketed version of remibrutinib through your local prescription or insurance coverage.
- You did not stop treatment early in the earlier study because of side effects or because the drug wasn't working.
- You are not taking any other medications that are not allowed during this study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new oral medication called remibrutinib for people with relapsing multiple sclerosis who are currently on Ocrevus. Participants will switch from Ocrevus to remibrutinib to see if it is safe and effective.
This trial tests an oral medication called remibrutinib to see if it can slow disability progression in people with secondary progressive multiple sclerosis (SPMS). You might join if you have had MS for a while, your symptoms have worsened over the past year, and you haven't had any recent relapses.
This study provides continued access to avapritinib for people who have already been in a Blueprint Medicines trial and are still benefiting from the drug. It allows you to keep receiving treatment while staying monitored for safety.
This trial continues to give pirtobrutinib to people with chronic lymphocytic leukemia or certain other lymphomas who were already in a previous study with this drug. It helps researchers keep track of long-term safety and how well the drug works over time.
This study tests the long-term safety and effectiveness of remibrutinib for people with moderate to severe hidradenitis suppurativa (HS) who have already completed a 68-week treatment period in a related study.
This study tests an experimental pill called remibrutinib in people with multiple sclerosis (MS). It uses MRI scans to see how well the drug works at reducing MS activity. This could help people with relapsing or progressive MS.
Hear when a new Indication of the Parent Protocol trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.